The AcrySof IQ PanOptix trifocal IOL, the first trifocal lens for cataract surgery patients in the United States, has been approved by the FDA, Alcon announced in a press release.
PanOptix, which is already available in more than 70 countries, has been shown to deliver a combination of near, intermediate and distance vision while significantly reducing the need for glasses after surgery, the release said. In a pivotal clinical study at 12 U.S. sites, more than 99% of PanOptix patients said they would choose the lens again, demonstrating high patient satisfaction.
- FDA approves Dexycu to treat cataract surgery inflammation
- Tracking cataract surgery outcomes leads to improved performance
“We are proud to bring this new class of IOLs to the largest eye care market in the world,” David J. Endicott, CEO of Alcon, said in the release. “We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.”
The company plans to begin training ophthalmologists in the U.S. and making the PanOptix and PanOptix toric IOLs available throughout the rest of the year and into early 2020. It will also launch a dedicated PanOptix website and multimedia awareness campaign, the release said.